Bioverativ Inc. is an American multinational

biotechnology Biotechnology is the integration of natural sciences and engineering sciences in order to achieve the application of organisms, cells, parts thereof and molecular analogues for products and services. The term ''biotechnology'' was first used ...

company that specializes in the discovery, development, and delivery of therapies for the treatment of

haemophilia Haemophilia, or hemophilia (), is a mostly inherited genetic disorder that impairs the body's ability to make blood clots, a process needed to stop bleeding. This results in people bleeding for a longer time after an injury, easy bruising, ...

. Bioverativ competes with Baxalta (acquired by

Shire Plc Shire plc was a UK-founded Jersey-registered specialty biopharmaceutical company. Originating in the United Kingdom with an operational base in the United States, its brands and products included Vyvanse, Lialda, and Adderall XR. Shire was ...

in 2016),

Pfizer Pfizer Inc. ( ) is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The company was established in 1849 in New York by two German entrepreneurs, Charles Pfizer ...

and

Novo Nordisk Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, with production facilities in nine countries, and affiliates or offices in five countries. Novo Nordisk is controlled by majority shareholder ...

. The company traded on the NASDAQ exchange under the ticker symbol BIVV until

Sanofi Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. Originally, the corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Syn ...

completed its acquisition on March 8, 2018.

History

In May 2016

Biogen Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. History ...

announced that it would spin off its hemophilia drug business (Eloctate and Alprolix) into a separate public company. In August, Biogen announced they would call the spun off company ''Bioverativ'' to show heritage with Biogen, and would be spun off in early 2017. On December 22, the Securities and Exchange Commission approved Bioverativ's registration statement, with the official separation date of the two companies being pegged at February 2017. In February, Biogen investors received a special dividend of one share of Bioverativ stock for every two shares of Biogen stock held as of January 17. Bioverativ began trading on January 12, 2017. In May 2017, the company announced it would acquire True North Therapeutics for $825 million, strengthening Bioverativ's pipeline with the acquisition of TNT009 – a treatment for

cold agglutinin disease Cold agglutinin disease (CAD) is a rare disease, rare autoimmune disease characterized by the presence of high concentrations of circulating cold sensitive antibodies, usually IgM and autoantibodies that are also active at temperatures below , dir ...

. In January 2018,

announced that it would acquire the business, for $11.6 billion.

Acquisition history

The following is an illustration of the company's major mergers and acquisitions and historical predecessors:

Products

The company has two current products; Alprolix and

Eloctate Efmoroctocog alfa, sold under the brand name Elocta among others, is a medication for the treatment and prophylaxis of bleeding in people with hemophilia A. Efmoroctocog alfa is a recombinant human coagulation factor VIII, Fc fusion protein (rF ...

, both products provided combined revenues of $604 million in 2015, and $640 million in the first nine months of 2016 (contributing to ~6% of Biogens' total revenue. These products are marketed in the United States, European Union, Japan, Canada and Australia.

References

{{reflist American companies established in 2016 Companies formerly listed on the Nasdaq Multinational companies headquartered in the United States Biotechnology companies established in 2016 Biotechnology companies of the United States Corporate spin-offs Sanofi 2018 mergers and acquisitions Pharmaceutical companies disestablished in 2018 American subsidiaries of foreign companies